The Efficacy of Thyrotropin Suppression Therapy in Treatment of Differentiated Thyroid Cancer after Total Thyroidectomy

Open access


Background: The aim of this prospective study was to assess the effect of the TSH suppression on both disease-free and overall survivals in patients with nonmetastatic differentiated thyroid cancer (DTC) after total thyroidectomy.

Patients & Methods: One hundred and forty eight patients with pathologically proved operable differentiated thyroid carcinoma were enrolled in this prospective study. Levothyroxin (L-T4) therapy was started in doses according to treatment groups. Patients were randomly assigned to receive either postoperative TSH suppression therapy in group I (76 patients) or nonsuppression therapy in group II (72 patients).

Results: During the period of follow up with a median 54 months, the disease-free survival for patients without TSH suppression therapy did not reach statistically significant difference comparing with those for patients with the suppression therapy (p=0.09). However, the difference was statistically significant for high-risk patients (p=0.04). On comparing both groups there was no statistically significant difference with regard to overall survival (p=0.17). The age of the patients more than 45 years, tumour size more than 4 cm and high-risk group were significant independent predictors for thyroid carcinoma-related relapse in univariate analysis. However, tumour size was the only significant factor in multivariate analysis.

Conclusion: Suppressive treatment with L-T4 therapy in patients with differentiated thyroid carcinoma should be individualised and balanced against the adverse effects. TSH suppression is indicated in patients with high-risk disease or recurrent tumour. Normalisation of serum TSH is preferred for long-term treatment of disease-free elderly patients with DTC and comorbidities.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] Ibrahim AS Khaled HM Mikhail NN Baraka H Kamel H. Cancer incidence in Egypt: results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol 2014; 2014:437971.

  • [2] Sherman SI. Thyroid carcinoma. Lancet 2003; 361(9356):501-511.

  • [3] Hundahl SA Fleming ID Fremgen AM Menck HR. A National Cancer Data Base report on 53856 cases of thyroid carcinoma treated in the U.S. 1985-1995. Cancer 1998; 83 (12):2638-2648.

  • [4] Esnaola NF Cantor SB Sherman SI Lee JE Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 2001; 130 (6): 921-930.

  • [5] Mazzaferri EL Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86 (4):1447-1463.

  • [6] Cooper DS Doherty GM Haugen BR Kloos RT Lee SL Mandel SJ et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009; 19(11):1167-1214.

  • [7] Hay ID Thompson GB Grant CS Bergstralh EJ Dvorak CE Gorman CA et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26(8): 879-885.

  • [8] Wartofsky L Van Nostrand D. Radioiodine treatment of well-differentiated thyroid cancer. Endocrine 2012; 42(3): 506-513.

  • [9] McGriff NJ Csako G Gourgiotis L Lori CG Pucino F Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002; 34(7-8): 554-564.

  • [10] Biondi B Filetti S Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005; 1: 32-40.

  • [11] Collet TH Gussekloo J Bauer DC den Elzen WP Cappola AR Balmer P et al. Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172(10):799-809.

  • [12] Sugitani I Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 2011; 150(6): 1250-1257.

  • [13] Biondi B Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20(2):135-146.

  • [14] Rongen HA Hoetelmans RM Bult A van Bennekom WP. Chemiluminescence and immunoassays. J Pharm Biomed Anal 1994; 12(4):433-462.

  • [15] Koszegi T. Immunoluminometric detection of human procalcitonin. J Biochem Biophys Methods 2002; 53(1-3):157-64.

  • [16] Cady B Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104: 947-953.

  • [17] Ichikawa Y Saito E Abe Y Homma M Muraki T. Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab 1976; 42(2): 395-398.

  • [18] Carayon P Thomas-Morvan C Castanas E Tubiana M. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab 1980; 51(4):915-920.

  • [19] Clark OH Gerend PL Goretzki P Nissenson RA. Characterization of the thyrotropin receptoradenylate cyclase system in neoplastic human thyroid tissue. J Clin Endocrinol Metab 1983; 57(1):140-147.

  • [20] Roger P Taton M Van Sande J Dumont JE. Mitogenic effects of thyrotropin and adenosine 3’ 5’-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 1988; 66(6):1158-1165.

  • [21] Goretzki PE Frilling A Simon D Roeher HD. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 1990; 118:48-63.

  • [22] Haugen BR Pacini F Reiners C Schlumberger M Ladenson PW Sherman SI et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84(11): 3877-3885.

  • [23] Mazzaferri EL Young RL Oertel JE Kemmerer WT Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 1977; 56(3):171-196.

  • [24] Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 2008; 93(4): 1167-1169.

  • [25] Cooper DS. TSH suppressive therapy: an overview of long-term clinical consequences. Hormones 2010; 9(1):57-59.

  • [26] Pujol P Daures JP Nsakala N Baldet L Bringer J Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81(12):4318-4323.

  • [27] Cooper DS Specker B Ho M Sperling M Ladenson PW Ross DS et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8(9):737-744.

  • [28] Jonklaas J Sarlis NJ Litofsky D Ain KB Bigos ST Brierley JD et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16(12):1229-1242.

  • [29] Mazzaferri EL Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97 (5): 418-428.

  • [30] Lang BH Chow SM Lo CY Law SC Lam KY. Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann Surg 2007; 246(1): 114-121.

  • [31] Sugitani I Kasai N Fujimoto Y Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004; 135(2):139-148.

  • [32] Hovens GC Stokkel MP Kievit J Corssmit EP Pereira AM Romijn JA Smit JW. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92(7): 2610-2615.

  • [33] Shah JP Loree TR Dharker D Strong EW Begg C Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992; 164 (6): 658-661.

  • [34] Andersen PE Kinsella J Loree TR Shaha AR Shah JP. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 1995; 170 (5): 467-470.

  • [35] Coburn MC Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 1992; 164 (6): 671-676.

  • [36] Voutilainen PE Multanen MM Leppäniemi AK Haglund CH Haapiainen RK Franssila KO. Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 2001; 11 (10): 953-957.

  • [37] Staunton MD. Thyroid cancer. A multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 1994; 20 (6): 613-621. 32 Niveen A. Abo-Touk Dalia H. Zayed

  • [38] Biondi B Fazio S Carella C Sabatini D Amato G Cittadini A et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1994; 78(5): 1028-1033.

  • [39] Gullu S Altuntas F Dincer I Erol C Kamel N. Effects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunction. Eur J Endocrinol 2004; 150(5): 655-661.

  • [40] Kung AW Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996; 81(3): 1232-1236.

Journal information
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 504 240 18
PDF Downloads 165 98 7